Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery

2006 ◽  
Vol 27 (7) ◽  
pp. 391-398 ◽  
Author(s):  
M HAJOS
Diagnosis ◽  
2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Taro Shimizu

Abstract Diagnostic errors are an internationally recognized patient safety concern, and leading causes are faulty data gathering and faulty information processing. Obtaining a full and accurate history from the patient is the foundation for timely and accurate diagnosis. A key concept underlying ideal history acquisition is “history clarification,” meaning that the history is clarified to be depicted as clearly as a video, with the chronology being accurately reproduced. A novel approach is presented to improve history-taking, involving six dimensions: Courtesy, Control, Compassion, Curiosity, Clear mind, and Concentration, the ‘6 C’s’. We report a case that illustrates how the 6C approach can improve diagnosis, especially in relation to artificial intelligence tools that assist with differential diagnosis.


2017 ◽  
Vol 13 (7S_Part_13) ◽  
pp. P662-P663
Author(s):  
Christina M. Coughlan ◽  
Athena Wang ◽  
Lisa Viltz ◽  
Heidi J. Chial ◽  
Huntington Potter

Molecules ◽  
2019 ◽  
Vol 24 (18) ◽  
pp. 3352 ◽  
Author(s):  
Carlos Alvarado ◽  
Erik Stahl ◽  
Karissa Koessel ◽  
Andrew Rivera ◽  
Brian R. Cherry ◽  
...  

The Focal Adhesion Targeting (FAT) domain of Focal Adhesion Kinase (FAK) is a promising drug target since FAK is overexpressed in many malignancies and promotes cancer cell metastasis. The FAT domain serves as a scaffolding protein, and its interaction with the protein paxillin localizes FAK to focal adhesions. Various studies have highlighted the importance of FAT-paxillin binding in tumor growth, cell invasion, and metastasis. Targeting this interaction through high-throughput screening (HTS) provides a challenge due to the large and complex binding interface. In this report, we describe a novel approach to targeting FAT through fragment-based drug discovery (FBDD). We developed two fragment-based screening assays—a primary SPR assay and a secondary heteronuclear single quantum coherence nuclear magnetic resonance (HSQC-NMR) assay. For SPR, we designed an AviTag construct, optimized SPR buffer conditions, and created mutant controls. For NMR, resonance backbone assignments of the human FAT domain were obtained for the HSQC assay. A 189-compound fragment library from Enamine was screened through our primary SPR assay to demonstrate the feasibility of a FAT-FBDD pipeline, with 19 initial hit compounds. A final total of 11 validated hits were identified after secondary screening on NMR. This screening pipeline is the first FBDD screen of the FAT domain reported and represents a valid method for further drug discovery efforts on this difficult target.


2001 ◽  
Vol 6 (12) ◽  
pp. 621-627 ◽  
Author(s):  
Klaus Früh ◽  
Kenneth Simmen ◽  
B.G.Mattias Luukkonen ◽  
Yolanda C Bell ◽  
Peter Ghazal

2014 ◽  
Vol 34 (6) ◽  
pp. 1242-1285 ◽  
Author(s):  
Shaoyong Lu ◽  
Shuai Li ◽  
Jian Zhang

Sign in / Sign up

Export Citation Format

Share Document